Interius BioTherapeutics Highlights Strong Preclinical Data Supporting In Vivo Chimeric Antigen Receptor (CAR) Vector Evaluation in Clinic

Interius BioTherapeutics, a leading developer of in vivo cell-specific genetic medicine therapeutics, announced the presentation of compelling preclinical data at the Cellicon Valley 2023 Meeting in Philadelphia, PA.